Evidence map›Paper›PMID 35227195›Full record

ArticleBMC gastroenterology2022

The methylation of SDC2 and TFPI2 defined three methylator phenotypes of colorectal cancer.

Ruixue Lei, Yanteng Zhao, Kai Huang, Qian Wang, Kangkang Wan, Tingting Li, Haijun Yang, Xianping Lv

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Ruixue Lei *Department of Pathology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang Tumor Hospital, Anyang, Henan, China.
Yanteng Zhao *Department of Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Kai Huang *Department of Gastrointestinal Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Qian WangDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Kangkang WanWuhan Ammunition Life-Tech Company, Ltd., Wuhan, Hubei, China.
Tingting LiWuhan Ammunition Life-Tech Company, Ltd., Wuhan, Hubei, China.
Haijun YangDepartment of Pathology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang Tumor Hospital, Anyang, Henan, China. yhj1972@126.com.
Xianping LvDepartment of Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. lvxianping@126.com.
First Affiliated Hospital of Zhengzhou University · CNAnhui Medical University · CNAnyang Tumor Hospital · CNHenan University of Science and Technology · CNZhongnan Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethylated SDC2 and TFPI2 are widely used for colorectal cancer (CRC) detection. However, they often miss some CRCs, which directly diminishes the sensitivity. Further investigations of the underlying mechanisms leading to the missed samples will facilitate developing more eligible methylation markers.

methodsCRC samples from TCGA and GEO datasets were divided into three groups, High-methylation/ High-methylation (HH), High-methylation/Low-methylation (HL), and Low-methylation/Low-methylation (LL) according to the methylation status of SDC2 and TFPI2 promoters. Variations in age, tumor location and microsatellite instable were then assessed between the three groups and verified in our custom cohort.

resultsSamples of HL group preferred to derive from left-sided CRCs (P < 0.05). HH samples showed the highest microsatellite instability and mutation load (mean nonsynonymous mutations for HH/HL/LL: 10.55/3.91/7.02, P = 0.0055). Almost all mutations of BRAF, one of the five typical CpG island methylator phenotype (CIMP) related genes, were observed in HH group (HH/HL/LL: 51/0/1, P = 0.018). Besides, older patients were frequently found in HH group. Expression analysis identified 37, 84, and 22 group-specific differentially expressed genes (DEGs) for HH, HL, and LL, respectively. Functional enrichment analysis revealed that HH-specific DEGs were mainly related to transcription regulation, while LL-specific DEGs were enriched in the biological processes of extracellular matrix interaction and cell migration.

conclusionsThe current study revealed that the performance of methylation-based markers might be affected by tumor location, patient age, mutation load and MSI, and these respective sides should be considered when developing new methylation markers for CRC detection.

Indexed as

Colorectal NeoplasmsDNA MethylationSyndecan-2CpG IslandsGlycoproteinsHumansMicrosatellite InstabilityMutationPhenotypeProto-Oncogene Proteins B-rafGlycoproteinsProto-Oncogene Proteins B-rafSDC2 protein, humanSyndecan-2tissue-factor-pathway inhibitor 2Colorectal cancerMethylationPhenotypesSDC2TFPI2

Identifiers

PMID35227195
PMCPMC8886827
OpenAlexW4220766329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.